Stocks › NBIX
NEUROCRINE BIOSCIENCES INC
NBIX·Nasdaq·
United States·USD
United States·USD$145.51
+1.30 (+0.90%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
NBIX
NEUROCRINE BIOSCIENCES INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
NBIXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of NBIX by members of U.S. Congress · 28 on record
Whale Activity
Position changes in NBIX reported for 2026-06-30 by 12 tracked institutional filers
- Increased4
- New1
- Held0
- Decreased5
- Closed0
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 13.7M | $2.31B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.0M | $838.3M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5M | $766.0M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 2.3M | $393.7M | decreased |
| TWO SIGMA INVESTMENTS, LP | 2.1M | $349.9M | decreased |
| Bridgewater Associates, LP | 205.7K | $34.7M | increased |
| Azimuth Capital Investment Management LLC | 112.5K | $19.0M | — |
| Palo Alto Investors LP | 18.1K | $3.1M | — |
| CITADEL ADVISORS LLC | 11.9K | $2.0M | decreased |
| MILLENNIUM MANAGEMENT LLC | 11.6K | $2.0M | decreased |
| D. E. Shaw & Co., Inc. | 5,599 | $944K | decreased |
| HARVEST MANAGEMENT LLC | 1,617 | $273K | new |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by NBIX insiders, by quarter · Form 4
Recent Insider Transactions
1,707 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Boyer David W.Chief Corp. Affairs Officer | Sale | −826 | $157.45 | $130K | Sep 14, 2026 | Form 4 ↗ |
| ABERNETHY MATTChief Financial Officer | Sale | −2,311 | $157.20 | $363K | Sep 14, 2026 | Form 4 ↗ |
| BENEVICH ERICChief Commercial Officer | Sale | −2,154 | $154.61 | $333K | Sep 9, 2026 | Form 4 ↗ |
| Norwalk Leslie VDirector · Director | Sale | −1,250 | $182.01 | $228K | Jul 28, 2026 | Form 4 ↗ |
| Delaet IngridChief Regulatory Officer | Sale | −4,367 | $181.02 | $791K | Jul 10, 2026 | Form 4 ↗ |
| Lippoldt DarinChief Legal Officer | Sale | −10.0K | $179.60 | $1.8M | Jul 9, 2026 | Form 4 ↗ |
| Delaet IngridChief Regulatory Officer | Sale | −8,433 | $178.72 | $1.5M | Jul 9, 2026 | Form 4 ↗ |
| Delaet IngridChief Regulatory Officer | Sale | −2,737 | $178.54 | $489K | Jul 8, 2026 | Form 4 ↗ |
| Delaet IngridChief Regulatory Officer | Sale | −3,401 | $178.57 | $607K | Jul 7, 2026 | Form 4 ↗ |
| Lippoldt DarinChief Legal Officer | Sale | −1,690 | $170.81 | $289K | Jun 29, 2026 | Form 4 ↗ |
| Lippoldt DarinChief Legal Officer | Option exercise | +1,690 | $81.49 | $138K | Jun 29, 2026 | Form 4 ↗ |
| Lippoldt DarinChief Legal Officer | Sale | −8,110 | $170.03 | $1.4M | Jun 29, 2026 | Form 4 ↗ |
| Lippoldt DarinChief Legal Officer | Option exercise | +8,110 | $81.49 | $661K | Jun 29, 2026 | Form 4 ↗ |
| Lippoldt DarinChief Legal Officer | Sale | −200 | $169.57 | $34K | Jun 26, 2026 | Form 4 ↗ |
| Lippoldt DarinChief Legal Officer | Option exercise | +200 | $81.49 | $16K | Jun 26, 2026 | Form 4 ↗ |
| Onyia JudeChief Scientific Officer | Gift | −2,441 | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| SHERWIN STEPHEN ADirector | Sale | −1,843 | $167.31 | $308K | Jun 5, 2026 | Form 4 ↗ |
| SHERWIN STEPHEN ADirector | Sale | −5,829 | $166.56 | $971K | Jun 5, 2026 | Form 4 ↗ |
| SHERWIN STEPHEN ADirector | Sale | −6,896 | $165.79 | $1.1M | Jun 5, 2026 | Form 4 ↗ |
| SHERWIN STEPHEN ADirector | Sale | −2,549 | $164.44 | $419K | Jun 5, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding NBIX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Dodge & Cox Stock Fund Dodge & Cox Funds | 4.0M | $668.1M | 0.56% | Jun 30, 2026 |
| iShares Core S&P Mid-Cap ETF iShares Trust | 3.4M | $579.9M | 0.47% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.2M | $538.2M | 0.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.3M | $388.5M | 0.21% | Jun 30, 2026 |
| JPMorgan Growth Advantage Fund J.P. Morgan Mutual Fund Investment Trust | 1.4M | $229.0M | 1.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.3M | $224.1M | 0.48% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.2M | $194.3M | 0.20% | Jun 30, 2026 |
| JPMorgan Mid Cap Growth Fund JPMorgan Trust II | 1.1M | $188.2M | 1.42% | Jun 30, 2026 |
| State Street SPDR S&P MidCap 400SM ETF Trust SPDR S&P MIDCAP 400 ETF TRUST | 773.6K | $130.4M | 0.46% | Jun 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 700.1K | $118.0M | 1.30% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list NBIX's shares (CUSIP 64125C109), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming neurocrine biosciences as client
- BGR GOVERNMENT AFFAIRSNEUROCRINE BIOSCIENCES, INC. · 2026 Q2 · PHA$60K
Filing ↗ - TARPLIN, DOWNS & YOUNG, LLCNEUROCRINE BIOSCIENCES, INC. · 2026 Q2 · HCR, MMM, BUD$110K
Filing ↗ - NEUROCRINE BIOSCIENCES, INCNEUROCRINE BIOSCIENCES, INC · 2026 Q2 · MMM, HCR, BUD, TAX$940K
Filing ↗ - CAPITOL COUNSEL LLCNEUROCRINE BIOSCIENCES, INC. · 2026 Q2 · BUD, HCR, MMM$60K
Filing ↗ - NEUROCRINE BIOSCIENCES, INCNEUROCRINE BIOSCIENCES, INC · 2026 Q1 · TAX, MMM, HCR, BUD$940K
Filing ↗
Government Contracts
Federal awards to NEUROCRINE BIOSCIENCES INC · USAspending
No federal contract awards found for NEUROCRINE BIOSCIENCES INC.
U.S. Patents
Recent USPTO applications naming NEUROCRINE BIOSCIENCES INC
No USPTO patent applications found for NEUROCRINE BIOSCIENCES INC.
Annual Financials
From NBIX's 10-K filings · XBRL
No annual XBRL figures on record for NBIX. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in NBIX's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.02Officer / director changeSep 28, 2026
EDGAR ↗ - 8-K/A · Items 9.01Jul 31, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 30, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07Officer / director change · Shareholder voteMay 28, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.01, 2.03, 7.01, 9.01Material agreement · Acquisition or disposition · Direct financial obligationMay 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
EDGAR ↗
About NEUROCRINE BIOSCIENCES INC
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
SEC CIK0000914475 ↗